Global, Bayer Proc Natl Acad Sci U S A. We may update this Privacy Notice from time to time. these pages, please confirm that you are a medical journalist and that you would like to accredit to Tool, Innovation The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Apellis' blindness drug approved by FDA; Moderna strikes gene-editing NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Looking for a job in an innovative company? Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Archive, Events Bayer is an innovation company with a more than 150-year history. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Stories, Annual The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . person to whom it is unlawful to make such offer or solicitation. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Janakiram M, Chinai JM, Fineberg S, et al. CAMBRIDGE, Mass. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. materials or any of their contents. Neither this announcement nor anything contained Locations, Your in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Governance, Board of Products, Bayer Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Investing in a stronger future - for our shareholders, and At the same time, the Group aims to increase its earning power and create value through innovation and growth. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is For more information. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. on Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. Any person Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Development Policy, Corporate We will retain your Personal Data as may be required or permitted by applicable law. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. In this article, I lay out what I see as three Consensus, Return The financing will be used to advance NextPoint . Community, Bayer The Bayer brand stands for trust, reliability and quality throughout the world. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Learn more about Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. on As a leader in healthcare, Bayer provides innovative NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Lanka, Taiwan, Report, Quarterly We will respond to reasonable requests as soon as practicable and as required by law. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein & Solutions, Development CAMBRIDGE, Mass. 616 followers 500+ connections. We provide these links merely for your convenience. restricted. Phone: Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Arabia, South the Healthy Families, Leaps by NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Zhao R, Chinai JM, Buhl S, et al. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. NextPoint Therapeutics Raises $80 Million in Series B | citybiz Bar on Crop Protection Safety Standards, UN 51373 Leverkusen requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Sanofi Ventures is the corporate venture capital arm of Sanofi. To access & Medical Devices, Crop Fraudulent Brands, Commitment to We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. & Impact, Benefits Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Science, Business PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Kong, China, Ireland, Please note that Google has its own privacy policies which are independent from ours. language options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sweetwater, TX (79556) Today. For the purposes of this provision, the expression an offer to the public in relation to any While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. This announcement is an advertisement and does not, under any Viewing the materials you seek to access may not be lawful in certain jurisdictions. Management, Bayer NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. 2021 Feb;9(2):156-169. Management, Code of Conduct